Royalty Pharma RPRX Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $2.44B+7.8% | $2.38B+5.1% | $2.35B+3.7% | $2.31B+3.0% | $2.26B+1.1% | ||
| $441.29M+749% | $452M+22,500% | $402M+20,000% | $352M+577% | $52M0.0% | ||
| $622.27M+115% | $573.48M+142% | $476.8M+109% | $414.79M+81.3% | $289.72M+30.7% | ||
| —— | —— | —— | —— | $0— | ||
| $852.15M+134% | $818.67M-15.7% | $817.19M+10.6% | $464.67M-64.1% | $363.45M-72.4% | ||
| $1.59B-16.4% | $1.56B+20.7% | $1.53B-0.7% | $1.84B+91.7% | $1.9B+102% | ||
| 65.1%-18.9pp | 65.6%+8.5pp | 65.2%-2.9pp | 79.8%+36.9pp | 83.9%+42.0pp | ||
| $336.13M+36.3% | $307.66M+36.4% | $279.25M+34.9% | $266.2M+42.7% | $246.54M+33.6% | ||
| $28.53M-44.3% | $33.59M-29.0% | $35.56M-20.6% | $46.16M-9.0% | $51.22M-18.7% | ||
| -$229.36M— | -$234.33M— | —— | —— | —— | ||
| $44.4M-11.6% | $29.09M-1.8% | $56.73M+3,304% | $51.19M+394% | $50.2M+353% | ||
| $1.36B-23.2% | $1.33B-0.4% | $1.3B-23.9% | $1.67B+61.8% | $1.77B+49.1% | ||
| $0— | $0— | $0— | $0— | $0— | ||
| $827.29M-24.3% | $771.95M-10.1% | $765.96M-33.1% | $1.02B+51.8% | $1.09B+36.9% | ||
| 33.9%-14.4pp | 32.5%-5.5pp | 32.6%-17.9pp | 44.3%+14.2pp | 48.3%+12.6pp | ||
| $1.91-22.4% | $1.79-6.8% | $1.76-31.0% | $2.30+53.3% | $2.46+39.0% | ||
| $1.91-22.7% | $1.79-7.3% | $1.76-31.5% | $2.31+53.0% | $2.47+38.0% | ||
| 2.2B-5.0% | 2.3B-4.9% | 2.3B-4.0% | 2.3B-3.0% | 2.4B-1.9% | ||
| 1.7B-3.4% | 1.7B-4.2% | 1.7B-3.1% | 1.8B-2.3% | 1.8B-0.7% | ||
| $89.6M— | $93.3M— | $93.3M— | $92.54M— | $0— | ||
| —— | —— | —— | —— | —— | ||
| $42.46M-59.6% | $45.86M-70.4% | $72.79M-65.7% | $77.99M-51.8% | $105.21M-57.1% | ||
| —— | —— | —— | —— | —— | ||
| $28.53M-44.3% | $33.59M-29.0% | $35.56M-20.6% | $46.16M-9.0% | $51.22M-18.7% | ||
| $311M+41.7% | $276.29M+73.1% | $270.42M+66.8% | $219.42M+32.4% | $219.42M+32.5% | ||
| —— | —— | —— | —— | —— | ||
| -$2.6B-24.4% | -$1.61B+39.7% | -$1.27B+59.9% | -$1.51B+38.0% | -$2.09B-30.4% | ||
| $2.61B-3.3% | $2.49B-10.1% | $2.41B-14.1% | $2.41B-9.8% | $2.7B+3.1% | ||
| -$13.49M-1,390% | -$14.35M-839% | -$8.37M+52.6% | -$8.45M+52.3% | -$905K+96.0% | ||
| $568.7M-39.4% | $1.23B+434% | $1.2B+479% | $1.15B+359% | $938.43M— | ||
| $2.15B-11.2% | $1.7B-32.2% | $1.46B-51.5% | $1.69B-25.3% | $2.42B+51.3% | ||
| $111.19M+102% | $105.15M+345% | $103.4M+313% | $113.98M+532% | $54.94M+290% | ||
| $12.96M-58.1% | $21.23M+7.3% | $30.93M+258% | $30.93M+437% | $30.93M+974% | ||
| -$389.29M-1,892% | -$318.94M-144% | -$154.91M— | -$394.65M— | $21.72M— | ||
| $1.59B-16.4% | $1.56B+20.7% | $1.53B-0.7% | $1.84B+91.7% | $1.9B+102% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Royalty Pharma's revenue?
- Royalty Pharma (RPRX) generated $2.4B in revenue over the trailing twelve months, up 7.8% year over year.
- Is Royalty Pharma profitable?
- Royalty Pharma reported $827.3M in net income over the trailing twelve months, a 33.9% net margin.
- What is Royalty Pharma's earnings per share?
- Royalty Pharma's diluted EPS over the trailing twelve months is $1.91.
- Where does Royalty Pharma's income statement data come from?
- Every line is extracted from Royalty Pharma's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
